BioNexus Gene Lab (BGLC) Cost of Revenue (2018 - 2026)

BioNexus Gene Lab (BGLC) has 9 years of Cost of Revenue data on file, last reported at $23632.0 in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue fell 98.68% year-over-year to $23632.0; the trailing twelve-month figure through Mar 2026 stood at $4.6 million (down 42.86% YoY), and the FY2025 full-year result was $6.3 million, down 22.89% from the prior year.
• Cost of Revenue retreated to $23632.0 in Q1 2026, from $487743.0 in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $2.7 million in Q1 2022 to a low of $23632.0 in Q1 2026.
• A 5-year average of $1.9 million and a median of $2.2 million in 2025 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue increased 12.24% in 2025 and slumped 98.68% in 2026, its largest moves.
• Tracing BGLC's Cost of Revenue over 5 years: stood at $2.5 million in 2022, then decreased by 19.75% to $2.0 million in 2023, then gained by 10.37% to $2.2 million in 2024, then tumbled by 77.98% to $487743.0 in 2025, then tumbled by 95.15% to $23632.0 in 2026.
• Business Quant data shows BGLC's Cost of Revenue at $23632.0 in Q1 2026, $487743.0 in Q4 2025, and $2.2 million in Q3 2025.